| Oct 1 |
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
|
| Sep 30 |
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
|
| Sep 25 |
Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now?
|
| Sep 10 |
Exploring 3 High Growth Tech Stocks in the United States
|
| Aug 26 |
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 15 |
John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc
|
| Aug 14 |
Paulson & Co. boosts Madrigal Pharma, exits Alibaba, others in Q2
|
| Aug 14 |
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
|
| Aug 13 |
Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected
|
| Aug 8 |
While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
|
